TY - JOUR T1 - Combined prenatal <em>Lactobacillus reuteri</em> and ω-3 supplementation synergistically modulates DNA methylation in neonatal T helper cells JF - medRxiv DO - 10.1101/2021.03.25.21254287 SP - 2021.03.25.21254287 AU - Johanna Huoman AU - David Martínez-Enguita AU - Elin Olsson AU - Jan Ernerudh AU - Lennart Nilsson AU - Karel Duchén AU - Mika Gustafsson AU - Maria C Jenmalm Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254287.abstract N2 - Background Environmental exposures may alter DNA methylation patterns of T helper cells. As T helper cells are instrumental for allergy development, changes in methylation patterns may constitute a mechanism of action for allergy preventive interventions. While epigenetic effects of separate perinatal probiotic or ω-3 fatty acid supplementation have been studied previously, the combined treatment has not been assessed. We aimed to investigate epigenome-wide DNA methylation patterns in cord blood samples from children in a randomised double-blind placebo-controlled allergy prevention trial using pre- and postnatal combined Lactobacillus reuteri and ω-3 fatty acid treatment. To this end, &gt;866 000 CpG sites (MethylationEPIC 850K array) in cord blood CD4+ T cells were examined in samples from all four study arms (double-treatment: n=18, single treatments: probiotics n=16, ω-3 n=15, and double placebo: n=14). Statistical and bioinformatic analyses identified treatment-associated differentially methylated CpGs and genes, which were used to identify treatment-induced network modules. Pathway analyses inferred biological relevance, and comparisons were made to an independent allergy data set.Results Comparing the active treatments to the double placebo group, most differentially methylated CpGs and genes were hypermethylated, suggesting induction of transcriptional inhibition. The double-treated group showed the largest number of differentially methylated CpGs, of which many were unique, suggesting synergy between interventions. Clusters within the double-treated network module consisted of immune-related pathways, including T cell receptor signalling, and antigen processing and presentation, with similar pathways revealed for the single-treatment modules. CpGs derived from differential methylation and network module analyses were enriched in an independent allergy data set, particularly in the double-treatment group, proposing treatment-induced DNA methylation changes as relevant for allergy development.Conclusion Prenatal L. reuteri and/or ω-3 fatty acid treatment results in hypermethylation and affects immune- and allergy-related pathways in neonatal T helper cells, with potentially synergistic effects between the interventions and relevance for allergic disease. Further studies need to address these findings on a transcriptional level, and whether the results associate to allergy development in the children. Understanding the role of DNA methylation in regulating effects of perinatal probiotic and ω-3 interventions may provide essential knowledge in the development of efficacious allergy preventive strategies.Material in electronic repository 12 Supplementary Figures, 11 Supplementary Tables mainly collected in Supplementary Appendix.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01542970Funding StatementThis study was supported by grants from the Swedish Research Council (2016-01698 and 2019-00989); the Swedish Heart and Lung Foundation (20140321 and 20170365); the Cancer and Allergy Foundation and the Medical Research Council of Southeast Sweden (FORSS-666771 and FORSS-758981).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Parents or legal guardians provided informed consent on behalf of the children prior to inclusion in the study. Ethical permission for this study has been granted by the Regional Ethics Committee for Human Research in Linkoeping (Dnr 2011/45-31).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.BMIQbeta mixture quantileCBMCcord blood mononuclear cellCFUcolony forming unitCpGCytosine-phosphate-GuanineDMCdifferentially methylated CpGDMGdifferentially methylated geneFDRfalse discovery rateGWgestational weekL. reuteriLactobacillus reuteriLPsingle-treated L.reuteri + placebo groupLωdouble-treated L.reuteri + ω-3 groupMDSmultidimensional scalingMMDmean methylation differencePBMCperipheral blood mononuclear cellPPdouble placebo groupPROOM-3PRObiotics and OMega-3 studyPωsingle-treated ω-3 + placebo groupSVDsingular value decompositionω-3omega-3 fatty acids ER -